The recent approval of intramuscular midazolam (Seizalam®) for acute treatment of status epilepticus (SE) is an important advancement for the treatment of epilepsy and chemical nerve agent exposures. However, effective treatments that improve neuropathic outcomes after SE becomes refractory to benzodiazepines is a common unmet need for both epilepsy and nerve agent researchers.
This virtual workshop will convene preclinical and clinical researchers, as well as relevant stakeholders to discuss and define the indications of potential therapeutics needed to improve outcomes following SE. Topics of discussion will include refractory SE, post SE neuropathology, current clinical trials, gaps in the research for follow-on treatments and barriers to transitioning therapies to the clinic. Outcomes of the workshop will include a clearer understanding of the unmet therapeutic needs and identification of key gaps in the research, increasing the potential for new therapeutics development.
Keynote Speakers
Jonathan Newmark, MD
Senior Medical Officer, Office of Biodefense Research and Surety National Institute of Allergy and Infectious Diseases;
Adjunct Professor of Neurology, F. Edward Hebert School of Medicine, Uniformed Services University of the Health Sciences
Department of Neurology, Washington DC Veterans Affairs Medical Center
Jaideep Kapur, MBBS, PhD
Eugene Meyer III, Professor of Neuroscience and Neurology
Director, University of Virginia, Brain Institute
Amy Brooks-Kayal, MD
Professor and Chair, Department of Neurology
Andrew John Gabor, MD, PhD Presidential Endowed Chair
Co-Director, UC Davis CounterACT Center of Excellence
University of California, Davis, School of Medicine
Pam Lein, PhD
Professor of Neurotoxicology
Chair, Department of Molecular Biosciences
Director, UC Davis CounterACT Center of Excellence
University of California, Davis, School of Veterinary Medicine